Publications

Type
Date
Drug Discovery
2018-09
TLC599 Phase I/II Study in Knee Osteoarthritis
Author(s) Chien-Chih Lai, Chao-Ching Chiang, Chyou-Shen Lee, Chi-Ching Chang, Hsiao-Yi Lin, Tien-Ling Chen, and Sheue-Fang Shih
Published 20th Asia Pacific League of Associations for Rheumatology Congress
Oncology
Clinical Development
2014-06
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors.
Author(s) Ghamande, S., Lin, C. C., Cho, D. C., Shapiro, G. I., Kwak, E. L., Silverman, M. H., Tseng, Y. L., Kuo, M. W., Mach, W. B., Hsu, S. C., Coleman, T., Yang, J. C., Cheng, A. L., Ghalib, M. H., Chuadhary, I., Goel, S.
Published Invest New Drugs.
32(3):445-51, 2014.
Oncology
Non-Clinical Development
2013-11
Monitoring tumor response with [18F] FMAU in a sarcoma-bearing mouse model after liposomal vinorelbine treatment.
Author(s) Chan P. C., Wu C. Y., Chang W. T., Lin C. Y., Tseng, Y. L., Liu R. S., Alauddin M. M., Lin W. J., Wang H. E.
Published Nucl Med Biol.
40(8):1035-42, 2013.
Oncology
Non-Clinical Development
Delivery Technology
2013-05
Tumor burden talks in cancer treatment with PEGylated liposomal drugs.
Author(s) Lin Y. Y., Kao H. W., Li J. J., Hwang J. J., Tseng, Y. L., Lin W. J., Lin M. H., Ting G., Wang H. E.
Published PLoS One.
10;8(5):e63078, 2013.
Oncology
Clinical Development
2012-02
A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor.
Author(s) Yang, S. H., Lin, C. C., Lin, Z. Z., Tseng, Y. L., and Hong, R. L.
Published Invest New Drugs,
30(1):282-289, 2012.
Oncology
Non-Clinical Development
Delivery Technology
2011-06
Pharmacokinetics and dosimetry of (111) In/(188) Re-labeled PEGylated liposomal drugs in two colon carcinoma-bearing mouse models.
Author(s) Lin, Y. Y., Chang, C. H., Li, J. J., Stabin, M. G., Chang, Y. J., Chen, L. C., Lin, M. H., Tseng, Y. L., Lin, W. J., Lee, T. W., Ting, G., Chang, C. A., Chen, F. D., Wang, H. E.
Published Cancer Biother Radiopharm.,
26(3):373-380, 2011.
Oncology
Non-Clinical Development
Delivery Technology
2009-12
Therapeutic efficacy evaluation of 111In-labeled PEGylated liposomal vinorelbine in murine colon carcinoma with multimodalities of molecular imaging.
Author(s) Chow, T. H., Lin, Y. Y., Hwang, J. J., Wang, H. E., Tseng, Y. L., Pang, V. F., Liu, R. S., Lin, W. J., Yang, C. S., and Ting, G.
Published Nucl. Med.,
50:2073-2081, 2009.
Oncology
Non-Clinical Development
Delivery Technology
2009-08
Evaluation of pharmacokinetics of 111In-labeled VNB-PEGylated liposomes after intraperitoneal and intravenous administration in a tumor/ascites mouse model.
Author(s) Lin, Y. Y., Li, J. J., Chang, C. H., Lu, Y. C., Hwang, J. J., Tseng, Y. L., Lin, W. J., Ting, G., and Wang, H. E.
Published Cancer Biother Radiopharm.,
24:453-460, 2009.
Oncology
Delivery Technology
2009-01
Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine.
Author(s) Drummond DC, Noble CO, Guo Z, Hayes ME, Park JW, Ou CJ, Tseng YL, Hong K, Kirpotin DB.
Published J Pharmacol Exp Ther.
328(1):321-30.
Oncology
Non-Clinical Development
Delivery Technology
2008-07
Diagnostic and therapeutic evaluation of 111In-vinorelbine-liposomes in a human colorectal carcinoma HT-29/luc-bearing animal model.
Author(s) Chow, T. H., Lin, Y. Y., Hwang, J. J., Wang, H. E., Tseng, Y. L., Pang, V. F., Wang, S. J., Whang-Peng, J., and Ting, G.
Published Nucl.Med.Biol., 35:623-634, 2008.
of
2
You are now leaving tlcbio.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

TLC provides this link as a service to website visitors. TLC is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

Click “Stay” or “X” to return to tlcbio.com or “Continue” to proceed.

Continue Stay